Eli Lilly and Company has reported new long-term results showing that EBGLYSS (lebrikizumab-lbkz) maintained durable skin clearance and relief from persistent itch for up to four years in patients with moderate-to-severe atopic dermatitis. Findings from the first year of the ADlong Phase 3b open-label extension study will be presented at the American Academy of Dermatology (AAD) Annual Meeting in Denver.
EBGLYSS, a selective interleukin-13 (IL-13) inhibitor, is administered once monthly as a maintenance therapy. The cytokine IL-13 plays a central role in driving type-2 inflammation underlying atopic dermatitis. In the ADlong study, most patients achieved sustained clinical responses—94% reached EASI-75, 75% achieved EASI-90, and 68% attained Investigator’s Global Assessment scores of 0 or 1 (“clear” or “almost clear”). Additionally, 78% reported significant itch improvement.
The majority of participants (77%) were treated with EBGLYSS monotherapy, and four out of five achieved outcomes without topical corticosteroids. Safety results from the first year were consistent with previous studies, with no new safety signals observed. The most common treatment-related events were conjunctivitis (6.9%) and injection-site reactions (0.6%).
“These data underscore our commitment to helping people achieve durable disease control and relief from the chronic symptoms of eczema,” said Adrienne Brown, president of Lilly Immunology.
Lilly holds exclusive rights to develop and commercialize EBGLYSS globally outside Europe, where its partner Almirall manages development and commercialization for dermatology indications. The ADlong study is ongoing and will continue for an additional year.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!